An Open Label, Phase I, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Volasertib in Combination With Decitabine in Patients ≥ 65 Years With Acute Myeloid Leukemia
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2019
Price : $35 *
At a glance
- Drugs Volasertib (Primary) ; Decitabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 14 Dec 2016 Status changed from active, no longer recruiting to discontinued.
- 28 Oct 2016 Planned End Date changed from 1 Aug 2019 to 1 Dec 2019.
- 28 Oct 2016 Planned primary completion date changed from 1 Aug 2018 to 1 Jan 2019.